Skip to content

Apogee Therapeutics, Inc. APGE Short- term Investments

Short- term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
IQVIA logo
IQVIAIQV
Exelixis logo
ExelixisEXEL
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s short- term investments?
Apogee Therapeutics, Inc. (APGE) reported short- term investments of $608.09M in Q1 2026.
How has Apogee Therapeutics, Inc.'s short- term investments changed year-over-year?
Apogee Therapeutics, Inc.'s short- term investments increased by 49.6% year-over-year, from $406.41M to $608.09M.
What is the long-term trend for Apogee Therapeutics, Inc.'s short- term investments?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s short- term investments has grown at a 47.0% compound annual growth rate (CAGR), from $277.14M to $598.64M.